Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2012

Open Access 01-12-2012 | Original investigation

Baseline comparison of three health utility measures and the feeling thermometer among participants in the action to control cardiovascular risk in diabetes trial

Authors: Dennis W Raisch, Patricia Feeney, David C Goff Jr, KM Venkat Narayan, Patrick J O’Connor, Ping Zhang, Don G Hire, Mark D Sullivan

Published in: Cardiovascular Diabetology | Issue 1/2012

Login to get access

Abstract

Background

Health utility (HU) measures are used as overall measures of quality of life and to determine quality adjusted life years (QALYs) in economic analyses. We compared baseline values of three HUs including Short Form 6 Dimensions (SF-6D), and Health Utilities Index, Mark II and Mark III (HUI2 and HUI3) and the feeling thermometer (FT) among type 2 diabetes participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. We assessed relationships between HU and FT values and patient demographics and clinical variables.

Methods

ACCORD was a randomized clinical trial to test if intensive controls of glucose, blood pressure and lipids can reduce the risk of major cardiovascular disease (CVD) events in type 2 diabetes patients with high risk of CVD. The health-related quality of life (HRQOL) sub-study includes 2,053 randomly selected participants. Interclass correlations (ICCs) and agreement between measures by quartile were used to evaluate relationships between HU’s and the FT. Multivariable regression models specified relationships between patient variables and each HU and the FT.

Results

The ICCs were 0.245 for FT/SF-6D, 0.313 for HUI3/SF-6D, 0.437 for HUI2/SF-6D, 0.338 for FT/HUI2, 0.337 for FT/HUI3 and 0.751 for HUI2/HUI3 (P < 0.001 for all). Common classification by quartile was found for the majority (62%) of values between HUI2 and HUI3, which was significantly (P < 0.001) higher than between other HUs and the FT: SF-6D/HUI3 = 40.8%, SF-6D/HUI2 = 40.9%, FT/HUI3 = 35.0%, FT/HUI2 = 34.9%, and FT/SF-6D = 31.9%. Common classification was higher between SF-6D/HUI2 and SF-6D/HUI3 (P < 0.001) than between FT/SF-6D, FT/HUI2, and FT/HUI3. The mean difference in HU values per patient ranged from −0.024 ± 0.225 for SF-6D/ HUI3 to −0.124 ± 0.133 for SF-6D/HUI2. Regression models were significant; clinical and demographic variables explained 6.1% (SF-6D) to 7.7% (HUI3) of the variance in HUs.

Conclusions

The agreements between the different HUs were poor except for the two HUI measures; therefore HU values derived different measures may not be comparable. The FT had low agreement with HUs. The relationships between HUs and demographic and clinical measures demonstrate how severity of diabetes and other clinical and demographic factors are associated with HUs and FT measures.

Trial registration

ClinicalTrials.gov Identifier: NCT00000620
Appendix
Available only for authorised users
Literature
1.
go back to reference Green C, Brazier J, Deverill M: Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics. 2000, 17 (2): 151-165. 10.2165/00019053-200017020-00004.CrossRefPubMed Green C, Brazier J, Deverill M: Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics. 2000, 17 (2): 151-165. 10.2165/00019053-200017020-00004.CrossRefPubMed
2.
go back to reference Valentine WJ, Bottomley JM, Palmer AJ, Brandle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M: PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabet Med. 2007, 24 (9): 982-1002. 10.1111/j.1464-5491.2007.02188.x.CrossRefPubMed Valentine WJ, Bottomley JM, Palmer AJ, Brandle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M: PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabet Med. 2007, 24 (9): 982-1002. 10.1111/j.1464-5491.2007.02188.x.CrossRefPubMed
3.
go back to reference Feeny D, Furlong W, Boyle M, Torrance GW: Multi-attribute health status classification systems, Health Utilities Index. Pharmacoeconomics. 1995, 7 (6): 490-502. 10.2165/00019053-199507060-00004.CrossRefPubMed Feeny D, Furlong W, Boyle M, Torrance GW: Multi-attribute health status classification systems, Health Utilities Index. Pharmacoeconomics. 1995, 7 (6): 490-502. 10.2165/00019053-199507060-00004.CrossRefPubMed
4.
go back to reference Kind P, Dolan P, Gudex C, Williams A: Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998, 316 (7133): 736-741. 10.1136/bmj.316.7133.736.PubMedCentralCrossRefPubMed Kind P, Dolan P, Gudex C, Williams A: Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998, 316 (7133): 736-741. 10.1136/bmj.316.7133.736.PubMedCentralCrossRefPubMed
5.
go back to reference Brazier JE, Roberts J: The estimation of a preference-based measure of health from the SF-12. Med Care. 2004, 42 (9): 851-859. 10.1097/01.mlr.0000135827.18610.0d.CrossRefPubMed Brazier JE, Roberts J: The estimation of a preference-based measure of health from the SF-12. Med Care. 2004, 42 (9): 851-859. 10.1097/01.mlr.0000135827.18610.0d.CrossRefPubMed
6.
go back to reference Schunemann HJ, Armstrong D, Degl'innocenti A, Wiklund I, Fallone CA, Tanser L, Van Zanten SV, Heels-Ansdell D, El-Dika S, Chiba N, et al: A randomized multicenter trial to evaluate simple utility elicitation techniques in patients with gastroesophageal reflux disease. Med Care. 2004, 42 (11): 1132-1142. 10.1097/00005650-200411000-00013.CrossRefPubMed Schunemann HJ, Armstrong D, Degl'innocenti A, Wiklund I, Fallone CA, Tanser L, Van Zanten SV, Heels-Ansdell D, El-Dika S, Chiba N, et al: A randomized multicenter trial to evaluate simple utility elicitation techniques in patients with gastroesophageal reflux disease. Med Care. 2004, 42 (11): 1132-1142. 10.1097/00005650-200411000-00013.CrossRefPubMed
7.
go back to reference Schunemann HJ, Griffith L, Stubbing D, Goldstein R, Guyatt GH: A clinical trial to evaluate the measurement properties of 2 direct preference instruments administered with and without hypothetical marker states. Med Decis Making. 2003, 23 (2): 140-149. 10.1177/0272989X03251243.CrossRefPubMed Schunemann HJ, Griffith L, Stubbing D, Goldstein R, Guyatt GH: A clinical trial to evaluate the measurement properties of 2 direct preference instruments administered with and without hypothetical marker states. Med Decis Making. 2003, 23 (2): 140-149. 10.1177/0272989X03251243.CrossRefPubMed
8.
go back to reference Rasanen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynanen OP, Roine R: Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review. Int J Technol Assess Health Care. 2006, 22 (2): 235-241.CrossRefPubMed Rasanen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynanen OP, Roine R: Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review. Int J Technol Assess Health Care. 2006, 22 (2): 235-241.CrossRefPubMed
9.
go back to reference Brazier J, Green C, McCabe C, Stevens K: Use of visual analog scales in economic evaluation. Expert Rev Pharmacoecon Outcomes Res. 2003, 3 (3): 293-302. 10.1586/14737167.3.3.293.CrossRefPubMed Brazier J, Green C, McCabe C, Stevens K: Use of visual analog scales in economic evaluation. Expert Rev Pharmacoecon Outcomes Res. 2003, 3 (3): 293-302. 10.1586/14737167.3.3.293.CrossRefPubMed
10.
go back to reference Harrison MJ, Bansback NJ, Marra CA, Drummond M, Tugwell PS, Boonen A: Valuing health for clinical and economic decisions: directions relevant for rheumatologists. J Rheumatol. 2011, 38 (8): 1770-1775. 10.3899/jrheum.110404.CrossRefPubMed Harrison MJ, Bansback NJ, Marra CA, Drummond M, Tugwell PS, Boonen A: Valuing health for clinical and economic decisions: directions relevant for rheumatologists. J Rheumatol. 2011, 38 (8): 1770-1775. 10.3899/jrheum.110404.CrossRefPubMed
11.
go back to reference Parkin D, Devlin N: Is there a case for using visual analogue scale valuations in cost-utility analysis?. Health Econ. 2006, 15 (7): 653-664. 10.1002/hec.1086.CrossRefPubMed Parkin D, Devlin N: Is there a case for using visual analogue scale valuations in cost-utility analysis?. Health Econ. 2006, 15 (7): 653-664. 10.1002/hec.1086.CrossRefPubMed
12.
go back to reference Torrance GW, Feeny D, Furlong W: Visual analog scales: do they have a role in the measurement of preferences for health states?. Med Decis Making. 2001, 21 (4): 329-334.CrossRefPubMed Torrance GW, Feeny D, Furlong W: Visual analog scales: do they have a role in the measurement of preferences for health states?. Med Decis Making. 2001, 21 (4): 329-334.CrossRefPubMed
13.
go back to reference Rashidi AA, Anis AH, Marra CA: Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients. Health Qual Life Outcomes. 2006, 4: 25-10.1186/1477-7525-4-25.PubMedCentralCrossRefPubMed Rashidi AA, Anis AH, Marra CA: Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients. Health Qual Life Outcomes. 2006, 4: 25-10.1186/1477-7525-4-25.PubMedCentralCrossRefPubMed
14.
go back to reference Hatoum HT, Brazier JE, Akhras KS: Comparison of the HUI3 with the SF-36 preference based SF-6D in a clinical trial setting. Value Health. 2004, 7 (5): 602-609. 10.1111/j.1524-4733.2004.75011.x.CrossRefPubMed Hatoum HT, Brazier JE, Akhras KS: Comparison of the HUI3 with the SF-36 preference based SF-6D in a clinical trial setting. Value Health. 2004, 7 (5): 602-609. 10.1111/j.1524-4733.2004.75011.x.CrossRefPubMed
15.
go back to reference Feeny D, Wu L, Eng K: Comparing short form 6D, standard gamble, and Health Utilities Index Mark 2 and Mark 3 utility scores: results from total hip arthroplasty patients. Qual Life Res. 2004, 13 (10): 1659-1670. 10.1007/s11136-004-6189-2.CrossRefPubMed Feeny D, Wu L, Eng K: Comparing short form 6D, standard gamble, and Health Utilities Index Mark 2 and Mark 3 utility scores: results from total hip arthroplasty patients. Qual Life Res. 2004, 13 (10): 1659-1670. 10.1007/s11136-004-6189-2.CrossRefPubMed
16.
go back to reference Barton GR, Bankart J, Davis AC, Summerfield QA: Comparing Utility Scores Before and After Hearing-Aid Provision : Results According to the EQ-5D, HUI3 and SF-6D. Appl Health Econ Health Policy. 2004, 3 (2): 103-105. 10.2165/00148365-200403020-00006.CrossRefPubMed Barton GR, Bankart J, Davis AC, Summerfield QA: Comparing Utility Scores Before and After Hearing-Aid Provision : Results According to the EQ-5D, HUI3 and SF-6D. Appl Health Econ Health Policy. 2004, 3 (2): 103-105. 10.2165/00148365-200403020-00006.CrossRefPubMed
17.
go back to reference O'Brien BJ, Spath M, Blackhouse G, Severens JL, Dorian P, Brazier J: A view from the bridge: agreement between the SF-6D utility algorithm and the Health Utilities Index. Health Econ. 2003, 12 (11): 975-981. 10.1002/hec.789.CrossRefPubMed O'Brien BJ, Spath M, Blackhouse G, Severens JL, Dorian P, Brazier J: A view from the bridge: agreement between the SF-6D utility algorithm and the Health Utilities Index. Health Econ. 2003, 12 (11): 975-981. 10.1002/hec.789.CrossRefPubMed
18.
go back to reference Huang ES, Shook M, Jin L, Chin MH, Meltzer DO: The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care. 2006, 29 (2): 259-264. 10.2337/diacare.29.02.06.dc05-1443.PubMedCentralCrossRefPubMed Huang ES, Shook M, Jin L, Chin MH, Meltzer DO: The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care. 2006, 29 (2): 259-264. 10.2337/diacare.29.02.06.dc05-1443.PubMedCentralCrossRefPubMed
19.
go back to reference Franks P, Hanmer J, Fryback DG: Relative disutilities of 47 risk factors and conditions assessed with seven preference-based health status measures in a national U.S. sample: toward consistency in cost-effectiveness analyses. Med Care. 2006, 44 (5)): 478-485.CrossRefPubMed Franks P, Hanmer J, Fryback DG: Relative disutilities of 47 risk factors and conditions assessed with seven preference-based health status measures in a national U.S. sample: toward consistency in cost-effectiveness analyses. Med Care. 2006, 44 (5)): 478-485.CrossRefPubMed
20.
go back to reference Pickard AS, Wang Z, Walton SM, Lee TA: Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?. Health Qual Life Outcomes. 2005, 3: 11-10.1186/1477-7525-3-11.PubMedCentralCrossRefPubMed Pickard AS, Wang Z, Walton SM, Lee TA: Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?. Health Qual Life Outcomes. 2005, 3: 11-10.1186/1477-7525-3-11.PubMedCentralCrossRefPubMed
21.
go back to reference Smith KJ, Hsu HE, Roberts MS, Kramer MK, Orchard TJ, Piatt GA, Seidel MC, Zgibor JC, Bryce CL: Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005–2007. Prev Chronic Dis. 2010, 7 (5): A109.PubMedCentralPubMed Smith KJ, Hsu HE, Roberts MS, Kramer MK, Orchard TJ, Piatt GA, Seidel MC, Zgibor JC, Bryce CL: Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005–2007. Prev Chronic Dis. 2010, 7 (5): A109.PubMedCentralPubMed
22.
go back to reference Maddigan SL, Feeny DH, Majumdar SR, Farris KB, Johnson JA: Health Utilities Index mark 3 demonstrated construct validity in a population-based sample with type 2 diabetes. J Clin Epidemiol. 2006, 59 (5): 472-477. 10.1016/j.jclinepi.2005.09.010.CrossRefPubMed Maddigan SL, Feeny DH, Majumdar SR, Farris KB, Johnson JA: Health Utilities Index mark 3 demonstrated construct validity in a population-based sample with type 2 diabetes. J Clin Epidemiol. 2006, 59 (5): 472-477. 10.1016/j.jclinepi.2005.09.010.CrossRefPubMed
23.
go back to reference Mo F, Morrison H, Choi BC, Vardy L: Evaluation and measurement of health-related quality of life for individuals with diabetes mellitus by Health Utilities Index Mark 3 (HUI3) system. ScientificWorldJournal. 2006, 6: 1412-1423.CrossRefPubMed Mo F, Morrison H, Choi BC, Vardy L: Evaluation and measurement of health-related quality of life for individuals with diabetes mellitus by Health Utilities Index Mark 3 (HUI3) system. ScientificWorldJournal. 2006, 6: 1412-1423.CrossRefPubMed
24.
go back to reference Maddigan SL, Feeny DH, Johnson JA: A comparison of the health utilities indices Mark 2 and Mark 3 in type 2 diabetes. Med Decis Making. 2003, 23 (6): 489-501. 10.1177/0272989X03258438.CrossRefPubMed Maddigan SL, Feeny DH, Johnson JA: A comparison of the health utilities indices Mark 2 and Mark 3 in type 2 diabetes. Med Decis Making. 2003, 23 (6): 489-501. 10.1177/0272989X03258438.CrossRefPubMed
25.
go back to reference Barton GR, Sach TH, Doherty M, Avery AJ, Jenkinson C, Muir KR: An assessment of the discriminative ability of the EQ-5Dindex, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions. Eur J Health Econ. 2008, 9 (3): 237-249. 10.1007/s10198-007-0068-z.CrossRefPubMed Barton GR, Sach TH, Doherty M, Avery AJ, Jenkinson C, Muir KR: An assessment of the discriminative ability of the EQ-5Dindex, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions. Eur J Health Econ. 2008, 9 (3): 237-249. 10.1007/s10198-007-0068-z.CrossRefPubMed
26.
go back to reference Ackermann RT, Edelstein SL, Venkat Narayan KM, Zhang P, Engelgau MM, Herman WH, Marrero DG: Changes in Health State Utilities With Changes in Body Mass in the Diabetes Prevention Program. Obesity (Silver Spring). 2009, 17 (12): 2176-2181. 10.1038/oby.2009.114.CrossRef Ackermann RT, Edelstein SL, Venkat Narayan KM, Zhang P, Engelgau MM, Herman WH, Marrero DG: Changes in Health State Utilities With Changes in Body Mass in the Diabetes Prevention Program. Obesity (Silver Spring). 2009, 17 (12): 2176-2181. 10.1038/oby.2009.114.CrossRef
27.
go back to reference Sach TH, Barton GR, Doherty M, Muir KR, Jenkinson C, Avery AJ: The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQol VAS and SF-6D. Int J Obes (Lond). 2007, 31 (1): 189-196. 10.1038/sj.ijo.0803365.CrossRef Sach TH, Barton GR, Doherty M, Muir KR, Jenkinson C, Avery AJ: The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQol VAS and SF-6D. Int J Obes (Lond). 2007, 31 (1): 189-196. 10.1038/sj.ijo.0803365.CrossRef
28.
go back to reference Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC, et al: Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007, 99 (12A)): 21i-33i.CrossRefPubMed Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC, et al: Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007, 99 (12A)): 21i-33i.CrossRefPubMed
29.
go back to reference Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, et al: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008, 358 (24): 2545-2559.CrossRefPubMed Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, et al: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008, 358 (24): 2545-2559.CrossRefPubMed
30.
go back to reference Sullivan MD, Anderson RT, Aron D, Atkinson HH, Bastien A, Chen GJ, Feeney P, Gafni A, Hwang W, Katz LA, et al: Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. Am J Cardiol. 2007, 99 (12A)): 90i-102i.CrossRefPubMed Sullivan MD, Anderson RT, Aron D, Atkinson HH, Bastien A, Chen GJ, Feeney P, Gafni A, Hwang W, Katz LA, et al: Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. Am J Cardiol. 2007, 99 (12A)): 90i-102i.CrossRefPubMed
31.
go back to reference Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, Cukierman T, Horowitz KR, Murray A, Launer LJ: The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol. 2007, 99 (12A)): 112i-122i.CrossRefPubMed Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, Cukierman T, Horowitz KR, Murray A, Launer LJ: The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol. 2007, 99 (12A)): 112i-122i.CrossRefPubMed
32.
go back to reference Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002, 21 (2): 271-292. 10.1016/S0167-6296(01)00130-8.CrossRefPubMed Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002, 21 (2): 271-292. 10.1016/S0167-6296(01)00130-8.CrossRefPubMed
33.
go back to reference McGraw K, Wong S: Forming inferences about some Intraclass correlation coefficients. Psychol Methods. 1996, 1: 30-48.CrossRef McGraw K, Wong S: Forming inferences about some Intraclass correlation coefficients. Psychol Methods. 1996, 1: 30-48.CrossRef
34.
go back to reference O'Reilly DJ, Xie F, Pullenayegum E, Gerstein HC, Greb J, Blackhouse GK, Tarride JE, Bowen J, Goeree RA: Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. Qual Life Res. 2011, 20 (6): 939-943. 10.1007/s11136-010-9828-9.CrossRefPubMed O'Reilly DJ, Xie F, Pullenayegum E, Gerstein HC, Greb J, Blackhouse GK, Tarride JE, Bowen J, Goeree RA: Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. Qual Life Res. 2011, 20 (6): 939-943. 10.1007/s11136-010-9828-9.CrossRefPubMed
35.
go back to reference Glasziou P, Alexander J, Beller E, Clarke P: Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. Health Qual Life Outcomes. 2007, 5: 21-10.1186/1477-7525-5-21.PubMedCentralCrossRefPubMed Glasziou P, Alexander J, Beller E, Clarke P: Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. Health Qual Life Outcomes. 2007, 5: 21-10.1186/1477-7525-5-21.PubMedCentralCrossRefPubMed
36.
go back to reference Clarke P, Gray A, Holman R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002, 22 (4): 340-349.CrossRefPubMed Clarke P, Gray A, Holman R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002, 22 (4): 340-349.CrossRefPubMed
37.
go back to reference Bagust A, Beale S: Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005, 14 (3): 217-230. 10.1002/hec.910.CrossRefPubMed Bagust A, Beale S: Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005, 14 (3): 217-230. 10.1002/hec.910.CrossRefPubMed
38.
go back to reference Matza LS, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM, Barber BL: Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res. 2007, 16 (7): 1251-1265. 10.1007/s11136-007-9226-0.CrossRefPubMed Matza LS, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM, Barber BL: Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res. 2007, 16 (7): 1251-1265. 10.1007/s11136-007-9226-0.CrossRefPubMed
39.
go back to reference Kaplan RM: The minimally clinically important difference in generic utility-based measures. COPD. 2005, 2 (1): 91-97. 10.1081/COPD-200052090.CrossRefPubMed Kaplan RM: The minimally clinically important difference in generic utility-based measures. COPD. 2005, 2 (1): 91-97. 10.1081/COPD-200052090.CrossRefPubMed
40.
go back to reference Robinson A, Loomes G, Jones-Lee M: Visual analog scales, standard gambles, and relative risk aversion. Med Decis Making. 2001, 21 (1): 17-27. 10.1177/0272989X0102100103.CrossRefPubMed Robinson A, Loomes G, Jones-Lee M: Visual analog scales, standard gambles, and relative risk aversion. Med Decis Making. 2001, 21 (1): 17-27. 10.1177/0272989X0102100103.CrossRefPubMed
41.
go back to reference Tsuchiya A, Brazier J, Roberts J: Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets. J Health Econ. 2005, 25 (2): 334-346.CrossRefPubMed Tsuchiya A, Brazier J, Roberts J: Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets. J Health Econ. 2005, 25 (2): 334-346.CrossRefPubMed
42.
go back to reference Xie F, Li SC, Luo N, Lo NN, Yeo SJ, Yang KY, Fong KY, Thumboo J: Comparison of the EuroQol and short form 6D in Singapore multiethnic Asian knee osteoarthritis patients scheduled for total knee replacement. Arthritis Rheum. 2007, 57 (6): 1043-1049. 10.1002/art.22883.CrossRefPubMed Xie F, Li SC, Luo N, Lo NN, Yeo SJ, Yang KY, Fong KY, Thumboo J: Comparison of the EuroQol and short form 6D in Singapore multiethnic Asian knee osteoarthritis patients scheduled for total knee replacement. Arthritis Rheum. 2007, 57 (6): 1043-1049. 10.1002/art.22883.CrossRefPubMed
43.
go back to reference Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, Esdaile JM, Anis AH: A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005, 60 (7): 1571-1582. 10.1016/j.socscimed.2004.08.034.CrossRefPubMed Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, Esdaile JM, Anis AH: A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005, 60 (7): 1571-1582. 10.1016/j.socscimed.2004.08.034.CrossRefPubMed
44.
go back to reference Wee HL, Machin D, Loke WC, Li SC, Cheung YB, Luo N, Feeny D, Fong KY, Thumboo J: Assessing differences in utility scores: a comparison of four widely used preference-based instruments. Value Health. 2007, 10 (4): 256-265. 10.1111/j.1524-4733.2007.00174.x.CrossRefPubMed Wee HL, Machin D, Loke WC, Li SC, Cheung YB, Luo N, Feeny D, Fong KY, Thumboo J: Assessing differences in utility scores: a comparison of four widely used preference-based instruments. Value Health. 2007, 10 (4): 256-265. 10.1111/j.1524-4733.2007.00174.x.CrossRefPubMed
45.
go back to reference Lloyd A, Sawyer W, Hopkinson P: Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Health. 2001, 4 (5): 392-400. 10.1046/j.1524-4733.2001.45029.x.CrossRefPubMed Lloyd A, Sawyer W, Hopkinson P: Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Health. 2001, 4 (5): 392-400. 10.1046/j.1524-4733.2001.45029.x.CrossRefPubMed
46.
go back to reference Dennett SL, Boye KS, Yurgin NR: The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Health. 2008, 11 (3): 478-486. 10.1111/j.1524-4733.2007.00260.x.CrossRefPubMed Dennett SL, Boye KS, Yurgin NR: The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Health. 2008, 11 (3): 478-486. 10.1111/j.1524-4733.2007.00260.x.CrossRefPubMed
47.
go back to reference Hayes AJ, Clarke PM, Voysey M, Keech A: Simulation of quality-adjusted survival in chronic diseases: an application in type 2 diabetes. Med Decis Making. 2011, 31 (4): 559-570. 10.1177/0272989X11409049.CrossRefPubMed Hayes AJ, Clarke PM, Voysey M, Keech A: Simulation of quality-adjusted survival in chronic diseases: an application in type 2 diabetes. Med Decis Making. 2011, 31 (4): 559-570. 10.1177/0272989X11409049.CrossRefPubMed
48.
go back to reference Belletti DA, Zacker C, Wogen J: Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States. Cardiovasc Diabetol. 2010, 9: 7-10.1186/1475-2840-9-7.PubMedCentralCrossRefPubMed Belletti DA, Zacker C, Wogen J: Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States. Cardiovasc Diabetol. 2010, 9: 7-10.1186/1475-2840-9-7.PubMedCentralCrossRefPubMed
49.
go back to reference Kuznik A, Mardekian J: Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999–2008. Cardiovasc Diabetol. 2011, 10: 31-10.1186/1475-2840-10-31.PubMedCentralCrossRefPubMed Kuznik A, Mardekian J: Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999–2008. Cardiovasc Diabetol. 2011, 10: 31-10.1186/1475-2840-10-31.PubMedCentralCrossRefPubMed
50.
go back to reference Norgaard ML, Andersson C, Hansen PR, Andersen SS, Vaag A, Schramm TK, Folke F, Kober L, Torp-Pedersen C, Gislason GH: Temporal trends in the initiation of glucose-lowering medications after a first-time myocardial infarction - a nationwide study between 1997 and 2006. Cardiovasc Diabetol. 2011, 10: 5-10.1186/1475-2840-10-5.PubMedCentralCrossRefPubMed Norgaard ML, Andersson C, Hansen PR, Andersen SS, Vaag A, Schramm TK, Folke F, Kober L, Torp-Pedersen C, Gislason GH: Temporal trends in the initiation of glucose-lowering medications after a first-time myocardial infarction - a nationwide study between 1997 and 2006. Cardiovasc Diabetol. 2011, 10: 5-10.1186/1475-2840-10-5.PubMedCentralCrossRefPubMed
51.
go back to reference Rahman M, Simmons RK, Hennings SH, Wareham NJ, Griffin SJ: Effect of screening for Type 2 diabetes on population-level self-rated health outcomes and measures of cardiovascular risk: 13-year follow-up of the Ely cohort. Diabet Med. 2012, 28. Rahman M, Simmons RK, Hennings SH, Wareham NJ, Griffin SJ: Effect of screening for Type 2 diabetes on population-level self-rated health outcomes and measures of cardiovascular risk: 13-year follow-up of the Ely cohort. Diabet Med. 2012, 28.
Metadata
Title
Baseline comparison of three health utility measures and the feeling thermometer among participants in the action to control cardiovascular risk in diabetes trial
Authors
Dennis W Raisch
Patricia Feeney
David C Goff Jr
KM Venkat Narayan
Patrick J O’Connor
Ping Zhang
Don G Hire
Mark D Sullivan
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2012
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-11-35

Other articles of this Issue 1/2012

Cardiovascular Diabetology 1/2012 Go to the issue